Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.11 USD | -1.83% | +0.43% | +72.68% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.68% | 1.52B | |
+9.76% | 115B | |
+11.91% | 106B | |
-2.79% | 21.96B | |
-14.11% | 21.87B | |
-5.29% | 19.21B | |
-3.20% | 18.08B | |
-38.57% | 17.71B | |
+6.41% | 14.32B | |
+35.38% | 12.42B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating